摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2S,3R,4S,5S,6R)-6-Hydroxymethyl-3-tetradecyloxy-tetrahydro-pyran-2,4,5-triol | 142025-89-6

中文名称
——
中文别名
——
英文名称
(2S,3R,4S,5S,6R)-6-Hydroxymethyl-3-tetradecyloxy-tetrahydro-pyran-2,4,5-triol
英文别名
(2S,3R,4S,5S,6R)-6-(hydroxymethyl)-3-tetradecoxyoxane-2,4,5-triol
(2S,3R,4S,5S,6R)-6-Hydroxymethyl-3-tetradecyloxy-tetrahydro-pyran-2,4,5-triol化学式
CAS
142025-89-6
化学式
C20H40O6
mdl
——
分子量
376.534
InChiKey
YLBUIXJXVBDIME-OBKDMQGPSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.6
  • 重原子数:
    26
  • 可旋转键数:
    15
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    99.4
  • 氢给体数:
    4
  • 氢受体数:
    6

文献信息

  • PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE
    申请人:NESTOR John J.
    公开号:US20140349928A1
    公开(公告)日:2014-11-27
    Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    本文描述了共价修饰肽和/或蛋白质的合成方法和治疗用途。共价修饰的肽和/或蛋白质可以提高基于肽和蛋白质的治疗药物的药理特性。
  • IMPROVED PEPTIDE PHARMACEUTICALS
    申请人:EUMEDERIS PHARMACEUTICALS, INC.
    公开号:US20150307550A1
    公开(公告)日:2015-10-29
    Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    本文描述了共价修饰肽和/或蛋白质的合成方法和治疗用途。共价修饰的肽和/或蛋白质可以改善基于肽和蛋白质的治疗药物的药理特性。
  • Peptide Pharmaceuticals
    申请人:EuMederis Pharmaceuticals, Inc.
    公开号:US20150031630A1
    公开(公告)日:2015-01-29
    Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    本文描述了共价修饰肽和/或蛋白质的合成方法和治疗用途。共价修饰的肽和/或蛋白质可以改善基于肽和蛋白质的治疗药物的药理特性。
  • Peptide pharmaceuticals
    申请人:EUMEDERIS PHARMACEUTICALS, INC.
    公开号:US10005817B2
    公开(公告)日:2018-06-26
    Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    本文描述了共价修饰肽和/或蛋白质的合成方法和治疗用途。共价修饰的肽和/或蛋白质可改善基于肽和蛋白质的疗法的药物特性。
  • Peptide pharmaceuticals for insulin resistance
    申请人:Nestor John J.
    公开号:US10471127B2
    公开(公告)日:2019-11-12
    Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    本文描述了共价修饰肽和/或蛋白质的合成方法和治疗用途。共价修饰的肽和/或蛋白质可改善基于肽和蛋白质的疗法的药物特性。
查看更多